# Jazz Pharmaceuticals

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/jazz-pharmaceuticals
Canonical HTML page: https://gethealthbrief.com/entity/jazz-pharmaceuticals

## Timeline

- **2026-03-18**: AACR Presentation Announcement — Zymeworks confirms multiple data sessions for Ziihera at the upcoming annual meeting.
- **2024-Q4**: Regulatory Progress — Advancement of Biologics License Application (BLA) filings for lead indications.
- **2023-06**: ASCO Data Release — Positive pivotal Phase 2 results in biliary tract cancer (BTC) showcased at ASCO.

## Recent coverage (1 stories)

### Zymeworks to Present New Ziihera® Data at 2026 AACR Annual Meeting
2026-03-18 13:11:51 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Zymeworks Inc. has announced a series of clinical and preclinical presentations for its lead asset, Ziihera® (zanidatamab-hrii), at the 2026 AACR Annual Meeting. The data will highlight the therapeutic potential of this HER2-targeted bispecific antibody across multiple oncology indications.
Full story: https://gethealthbrief.com/story/zymeworks-ziihera-aacr-2026-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.